For research use only. Not for therapeutic Use.
SMIP004(Cat No.:I001674)is a compound that inhibits the SKP2 E3 ligase enzyme, leading to the downregulation of SKP2 and stabilization of the p27 protein. In addition, it selectively induces apoptosis, or programmed cell death, in human prostate cancer cells. By targeting the SKP2 pathway, SMIP004 has the potential as a therapeutic agent for prostate cancer, as it can regulate cell cycle progression and induce cell death in cancer cells. Its ability to selectively induce apoptosis also suggests that it may have minimal toxicity to normal cells.
Catalog Number | I001674 |
CAS Number | 143360-00-3 |
Synonyms | N-(4-butyl-2-methylphenyl)acetamide |
Molecular Formula | C13H19NO |
Purity | ≥95% |
Target | Apoptosis Inducers |
Solubility | DMSO 100mg/ml |
Storage | Store at -20°C |
IC50 | 1.09 uM (MTT assay in LNCaP-S14 cells) |
IUPAC Name | N-(4-butyl-2-methylphenyl)acetamide |
InChI | InChI=1S/C13H19NO/c1-4-5-6-12-7-8-13(10(2)9-12)14-11(3)15/h7-9H,4-6H2,1-3H3,(H,14,15) |
InChIKey | ZFVMECVBUGMWIX-UHFFFAOYSA-N |
SMILES | CCCCC1=CC(=C(C=C1)NC(=O)C)C |
Reference | <p style=/line-height:25px/> <br>[2]. Rico-Bautista E, Zhu W, Kitada S, Small Molecule-Induced Mitochondrial Disruption Directs Prostate Cancer Inhibition via UPR Signaling. Oncotarget. 2013 Jul 14. </p> |